{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T06:40:25Z","timestamp":1738651225466,"version":"3.35.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,3]]},"DOI":"10.7759\/cureus.78461","type":"journal-article","created":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T06:02:51Z","timestamp":1738648971000},"source":"Crossref","is-referenced-by-count":0,"title":["Salvage Surgery for Epidermal Growth Factor Receptor-Mutant Lung Cancer With Osimertinib Resistance: A Case Report"],"prefix":"10.7759","author":[{"given":"Shinya","family":"Otsuka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutaro","family":"Nagano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Shioya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroya","family":"Ohkawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuya","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2304594","article-title":"Overall survival with osimertinib in resected EGFR-mutated NSCLC","volume":"389","author":"Tsuboi M","year":"2023","unstructured":"Tsuboi M, Herbst RS, John T, et al.. Overall survival with osimertinib in resected EGFR-mutated NSCLC. N Engl J Med. 2023, 389:137-47. 10.1056\/NEJMoa2304594","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2310532","article-title":"Alectinib in resected ALK-positive non-small-cell lung cancer","volume":"390","author":"Wu YL","year":"2024","unstructured":"Wu YL, Dziadziuszko R, Ahn JS, et al.. Alectinib in resected ALK-positive non-small-cell lung cancer. N Engl J Med. 2024, 390:1265-76. 10.1056\/NEJMoa2310532","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria JC","year":"2018","unstructured":"Soria JC, Ohe Y, Vansteenkiste J, et al.. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018, 378:113-25. 10.1056\/NEJMoa1713137","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC","volume":"382","author":"Ramalingam SS","year":"2020","unstructured":"Ramalingam SS, Vansteenkiste J, Planchard D, et al.. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 2020, 382:41-50. 10.1056\/NEJMoa1913662","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.2969","article-title":"Assessment of resistance mechanisms and clinical implications in patients with EGFR T790M-positive lung cancer and acquired resistance to osimertinib","volume":"4","author":"Oxnard GR","year":"2018","unstructured":"Oxnard GR, Hu Y, Mileham KF, et al.. Assessment of resistance mechanisms and clinical implications in patients with EGFR T790M-positive lung cancer and acquired resistance to osimertinib. JAMA Oncol. 2018, 4:1527-34. 10.1001\/jamaoncol.2018.2969","journal-title":"JAMA Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.113469","article-title":"A phase II study of atezolizumab with bevacizumab, carboplatin, and paclitaxel for patients with EGFR-mutated NSCLC after TKI treatment failure (NEJ043 study)","volume":"197","author":"Watanabe S","year":"2024","unstructured":"Watanabe S, Furuya N, Nakamura A, et al.. A phase II study of atezolizumab with bevacizumab, carboplatin, and paclitaxel for patients with EGFR-mutated NSCLC after TKI treatment failure (NEJ043 study). Eur J Cancer. 2024, 197:113469. 10.1016\/j.ejca.2023.113469","journal-title":"Eur J Cancer"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.10.117","article-title":"Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study","volume":"35","author":"Passaro A","year":"2024","unstructured":"Passaro A, Wang J, Wang Y, et al.. Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study. Ann Oncol. 2024, 35:77-90. 10.1016\/j.annonc.2023.10.117","journal-title":"Ann Oncol"},{"key":"ref8","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events (CTACE) version 5.0. (2017). Accessed: January 30, 2025: https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_5x7.pdf."},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.13646","article-title":"Outcomes of salvage lung resections in advanced EGFR-mutant lung adenocarcinomas under EGFR TKIs","volume":"12","author":"Chen YY","year":"2021","unstructured":"Chen YY, Yen YT, Lai WW, Huang WL, Chang CC, Tseng YL. Outcomes of salvage lung resections in advanced EGFR-mutant lung adenocarcinomas under EGFR TKIs. Thorac Cancer. 2021, 12:2655-65. 10.1111\/1759-7714.13646","journal-title":"Thorac Cancer"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2020.12.037","article-title":"Salvage surgery for non-small cell lung cancer after tyrosine kinase inhibitor treatment","volume":"153","author":"Ohtaki Y","year":"2021","unstructured":"Ohtaki Y, Shimizu K, Suzuki H, et al.. Salvage surgery for non-small cell lung cancer after tyrosine kinase inhibitor treatment. Lung Cancer. 2021, 153:108-16. 10.1016\/j.lungcan.2020.12.037","journal-title":"Lung Cancer"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.athoracsur.2023.01.027","article-title":"Salvage surgery for advanced lung adenocarcinoma after epidermal growth factor receptor tyrosine kinase inhibitor treatment","volume":"116","author":"Lin MW","year":"2023","unstructured":"Lin MW, Yu SL, Hsu YC, et al.. Salvage surgery for advanced lung adenocarcinoma after epidermal growth factor receptor tyrosine kinase inhibitor treatment. Ann Thorac Surg. 2023, 116:111-9. 10.1016\/j.athoracsur.2023.01.027","journal-title":"Ann Thorac Surg"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00071","article-title":"Neoadjuvant osimertinib for the treatment of stage I-IIIA epidermal growth factor receptor-mutated non-small cell lung cancer: a phase II multicenter study","volume":"42","author":"Blakely CM","year":"2024","unstructured":"Blakely CM, Urisman A, Gubens MA, et al.. Neoadjuvant osimertinib for the treatment of stage I-IIIA epidermal growth factor receptor-mutated non-small cell lung cancer: a phase II multicenter study. J Clin Oncol. 2024, 42:3105-14. 10.1200\/JCO.24.00071","journal-title":"J Clin Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-0780","article-title":"The EGFR exon 19 mutant L747-A750>P exhibits distinct sensitivity to tyrosine kinase inhibitors in lung adenocarcinoma","volume":"25","author":"Truini A","year":"2019","unstructured":"Truini A, Starrett JH, Stewart T, et al.. The EGFR exon 19 mutant L747-A750>P exhibits distinct sensitivity to tyrosine kinase inhibitors in lung adenocarcinoma. Clin Cancer Res. 2019, 25:6382-91. 10.1158\/1078-0432.CCR-19-0780","journal-title":"Clin Cancer Res"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2019.09.015","article-title":"Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer","volume":"61","author":"Harrison PT","year":"2020","unstructured":"Harrison PT, Vyse S, Huang PH. Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer. Semin Cancer Biol. 2020, 61:167-79. 10.1016\/j.semcancer.2019.09.015","journal-title":"Semin Cancer Biol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/crj.13748","article-title":"The impact of EGFR T790M mutation status following the development of Osimertinib resistance on the efficacy of Osimertinib in non-small cell lung cancer: a meta-analysis","volume":"18","author":"Guo L","year":"2024","unstructured":"Guo L, Zhou G, Huang M, Tang K, Xu J, Chen J. The impact of EGFR T790M mutation status following the development of Osimertinib resistance on the efficacy of Osimertinib in non-small cell lung cancer: a meta-analysis. Clin Respir J. 2024, 18:e13748. 10.1111\/crj.13748","journal-title":"Clin Respir J"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/337037-salvage-surgery-for-epidermal-growth-factor-receptor-mutant-lung-cancer-with-osimertinib-resistance-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T06:02:52Z","timestamp":1738648972000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/337037-salvage-surgery-for-epidermal-growth-factor-receptor-mutant-lung-cancer-with-osimertinib-resistance-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,3]]},"references-count":15,"URL":"https:\/\/doi.org\/10.7759\/cureus.78461","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2,3]]}}}